|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
3
|
Mathé EA, Nguyen GH, Bowman ED, et al:
MicroRNA expression in squamous cell carcinoma and adenocarcinoma
of the esophagus: associations with survival. Clin Cancer Res.
15:6192–6200. 2009.PubMed/NCBI
|
|
4
|
Song QK, Li J, Jiang HD, He YM, Zhou XQ
and Huang CY: Esophageal cancer mortality during 2004–2009 in
Yanting County, China. Asian Pac J Cancer Prev. 13:5003–5006.
2012.
|
|
5
|
Fareed KR, Kaye P, Soomro IN, et al:
Biomarkers of response to therapy in oesophago-gastric cancer. Gut.
58:127–143. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pillai RS: MicroRNA function: multiple
mechanisms for a tiny RNA? RNA. 11:1753–1761. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rosenfeld N, Aharonov R, Meiri E, et al:
MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol.
26:462–469. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schmidt M, De Maziere A, Smyczek T, et al:
The role of Egfl7 in vascular morphogenesis. Novartis Found Symp.
283:18–28; discussion 28–36, 238–241. 2007. View Article : Google Scholar
|
|
13
|
Schmidt M, Paes K, De Maziere A, et al:
EGFL7 regulates the collective migration of endothelial cells by
restricting their spatial distribution. Development. 134:2913–2923.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li XM, Wang AM, Zhang J and Yi H:
Downregulation of miR-126 expression in colorectal cancer and its
clinical significance. Med Oncol. 28:1054–1057. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang J, Lan H, Huang X, Liu B and Tong Y:
MicroRNA-126 inhibits tumor cell growth and its expression level
correlates with poor survival in non-small cell lung cancer
patients. PLoS One. 7:e429782012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Otsubo T, Akiyama Y, Hashimoto Y, Shimada
S, Goto K and Yuasa Y: MicroRNA-126 inhibits SOX2 expression and
contributes to gastric carcinogenesis. PLoS One. 6:e166172011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sasahira T, Kurihara M, Bhawal UK, et al:
Downregulation of miR-126 induces angiogenesis and
lymphangiogenesis by activation of VEGF-A in oral cancer. Br J
Cancer. 107:700–706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Crawford M, Brawner E, Batte K, et al:
MicroRNA-126 inhibits invasion in non-small cell lung carcinoma
cell lines. Biochem Biophys Res Commun. 373:607–612. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ye P, Liu J, He F, Xu W and Yao K:
Hypoxia-induced deregulation of miR-126 and its regulative effect
on VEGF and MMP-9 expression. Int J Med Sci. 11:17–23. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li N, Li X, Huang S, Shen S and Wang X:
miR-126 inhibits colon cancer proliferation and invasion through
targeting IRS1, SLC7A5 and TOM1 gene. Zhong Nan Da Xue Xue Bao Yi
Xue Ban. 38:809–817. 2013.(In Chinese).
|
|
21
|
Lu YY, Sweredoski MJ, Huss D, Lansford R,
Hess S and Tirrell DA: Prometastatic GPCR CD97 is a direct target
of tumor suppressor microRNA-126. ACS Chem Biol. 9:334–338. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Y, Wang Z, Chen M, et al:
MicroRNA-143 targets MACC1 to inhibit cell invasion and migration
in colorectal cancer. Mol Cancer. 11:232012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao X, Dou W, He L, et al: MicroRNA-7
functions as an anti-metastatic microRNA in gastric cancer by
targeting insulin-like growth factor-1 receptor. Oncogene.
32:1363–1372. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tsuchiya S: The role of microRNA-210 in
esophageal squamous cell carcinoma. Yakugaku Zasshi. 132:1069–1073.
2012.(In Japanese).
|
|
26
|
Yang R, Dick M, Marme F, et al: Genetic
variants within miR-126 and miR-335 are not associated with breast
cancer risk. Breast Cancer Res Treat. 127:549–554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
White MF: IRS proteins and the common path
to diabetes. Am J Physiol Endocrinol Metab. 283:E413–E422. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Porter HA, Perry A, Kingsley C, Tran NL
and Keegan AD: IRS1 is highly expressed in localized breast tumors
and regulates the sensitivity of breast cancer cells to
chemotherapy, while IRS2 is highly expressed in invasive breast
tumors. Cancer Lett. 338:239–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shi B, Sepp-Lorenzino L, Prisco M, Linsley
P, deAngelis T and Baserga R: Micro RNA 145 targets the insulin
receptor substrate-1 and inhibits the growth of colon cancer cells.
J Biol Chem. 282:32582–32590. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yin Y, Yan ZP, Lu NN, et al:
Downregulation of miR-145 associated with cancer progression and
VEGF transcriptional activation by targeting N-RAS and IRS1.
Biochim Biophys Acta. 1829:239–247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Scott KL, Kabbarah O, Liang MC, et al:
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in
cancer. Nature. 459:1085–1090. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hua X, Yu L, Pan W, et al: Increased
expression of Golgi phosphoprotein-3 is associated with tumor
aggressiveness and poor prognosis of prostate cancer. Diagn Pathol.
7:1272012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hu BS, Hu H, Zhu CY, Gu YL and Li JP:
Overexpression of GOLPH3 is associated with poor clinical outcome
in gastric cancer. Tumour Biol. 34:515–520. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang JH, Chen XT, Wen ZS, et al: High
expression of GOLPH3 in esophageal squamous cell carcinoma
correlates with poor prognosis. PLoS One. 7:e456222012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li N, Tang A, Huang S, et al: MiR-126
suppresses colon cancer cell proliferation and invasion via
inhibiting RhoA/ROCK signaling pathway. Mol Cell Biochem.
380:107–119. 2013. View Article : Google Scholar : PubMed/NCBI
|
